Neutral impactResults

Jubilant Pharmova Q2 Review: Nirmal Bang Raises Target Price, Bets On H2 Margin Recovery

NDTV Profit 40 min ago·17 Nov 2026, 5:34 am

Jubilant Pharmova's revenue growth remains healthy during the quarter, but earnings are being held back by the SPECT supply gap and Montreal remediation costs, says Nirmal Bang.

Affected stocks

Neutral1 stock

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

  • Concerns Jubilant Pharmova (JUBLPHARMA).
  • Category: Results.

Why it matters

A routine update for Jubilant Pharmova. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at NDTV Profit.

More Stocks news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.